Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition
Acetylsalicylic acid (ASA) is one of the most frequently used medications worldwide. Yet, the main indications for ASA are the atherosclerosis-based cardiovascular diseases, including coronary artery disease (CAD). Despite the increasing number of percutaneous procedures to treat CAD, coronary arter...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/11/2317 |
| _version_ | 1797532631280123904 |
|---|---|
| author | Dominika Siwik Magdalena Gajewska Katarzyna Karoń Kinga Pluta Mateusz Wondołkowski Radosław Wilimski Łukasz Szarpak Krzysztof J. Filipiak Aleksandra Gąsecka |
| author_facet | Dominika Siwik Magdalena Gajewska Katarzyna Karoń Kinga Pluta Mateusz Wondołkowski Radosław Wilimski Łukasz Szarpak Krzysztof J. Filipiak Aleksandra Gąsecka |
| author_sort | Dominika Siwik |
| collection | DOAJ |
| description | Acetylsalicylic acid (ASA) is one of the most frequently used medications worldwide. Yet, the main indications for ASA are the atherosclerosis-based cardiovascular diseases, including coronary artery disease (CAD). Despite the increasing number of percutaneous procedures to treat CAD, coronary artery bypass grafting (CABG) remains the treatment of choice in patients with multivessel CAD and intermediate or high anatomical lesion complexity. Taking into account that CABG is a potent activator of inflammation, ASA is an important part in the postoperative therapy, not only due to ASA antiplatelet action, but also as an anti-inflammatory agent. Additional benefits of ASA after CABG include anticancerogenic, hypotensive, antiproliferative, anti-osteoporotic, and neuroprotective effects, which are especially important in patients after CABG, prone to hypertension, graft occlusion, atherosclerosis progression, and cognitive impairment. Here, we discuss the pleiotropic effects of ASA after CABG and provide insights into the mechanisms underlying the benefits of treatment with ASA, beyond platelet inhibition. Since some of ASA pleiotropic effects seem to increase the risk of bleeding, it could be considered a starting point to investigate whether the increase of the intensity of the treatment with ASA after CABG is beneficial for the CABG group of patients. |
| first_indexed | 2024-03-10T11:03:00Z |
| format | Article |
| id | doaj.art-f775877c21c84420aa7248733ae996c1 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T11:03:00Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-f775877c21c84420aa7248733ae996c12023-11-21T21:24:29ZengMDPI AGJournal of Clinical Medicine2077-03832021-05-011011231710.3390/jcm10112317Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet InhibitionDominika Siwik0Magdalena Gajewska1Katarzyna Karoń2Kinga Pluta3Mateusz Wondołkowski4Radosław Wilimski5Łukasz Szarpak6Krzysztof J. Filipiak7Aleksandra Gąsecka81st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, PolandDepartment of Cardiac Surgery, Medical University of Warsaw, 02-097 Warsaw, PolandDepartment of Cardiac Surgery, Medical University of Warsaw, 02-097 Warsaw, PolandBialystok Oncology Center, 15-027 Bialystok, Poland1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, PolandAcetylsalicylic acid (ASA) is one of the most frequently used medications worldwide. Yet, the main indications for ASA are the atherosclerosis-based cardiovascular diseases, including coronary artery disease (CAD). Despite the increasing number of percutaneous procedures to treat CAD, coronary artery bypass grafting (CABG) remains the treatment of choice in patients with multivessel CAD and intermediate or high anatomical lesion complexity. Taking into account that CABG is a potent activator of inflammation, ASA is an important part in the postoperative therapy, not only due to ASA antiplatelet action, but also as an anti-inflammatory agent. Additional benefits of ASA after CABG include anticancerogenic, hypotensive, antiproliferative, anti-osteoporotic, and neuroprotective effects, which are especially important in patients after CABG, prone to hypertension, graft occlusion, atherosclerosis progression, and cognitive impairment. Here, we discuss the pleiotropic effects of ASA after CABG and provide insights into the mechanisms underlying the benefits of treatment with ASA, beyond platelet inhibition. Since some of ASA pleiotropic effects seem to increase the risk of bleeding, it could be considered a starting point to investigate whether the increase of the intensity of the treatment with ASA after CABG is beneficial for the CABG group of patients.https://www.mdpi.com/2077-0383/10/11/2317acetylsalicylic acidASACABGcoronary artery bypass graftingAlzheimer’s diseasehypertension |
| spellingShingle | Dominika Siwik Magdalena Gajewska Katarzyna Karoń Kinga Pluta Mateusz Wondołkowski Radosław Wilimski Łukasz Szarpak Krzysztof J. Filipiak Aleksandra Gąsecka Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition Journal of Clinical Medicine acetylsalicylic acid ASA CABG coronary artery bypass grafting Alzheimer’s disease hypertension |
| title | Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition |
| title_full | Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition |
| title_fullStr | Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition |
| title_full_unstemmed | Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition |
| title_short | Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition |
| title_sort | pleiotropic effects of acetylsalicylic acid after coronary artery bypass grafting beyond platelet inhibition |
| topic | acetylsalicylic acid ASA CABG coronary artery bypass grafting Alzheimer’s disease hypertension |
| url | https://www.mdpi.com/2077-0383/10/11/2317 |
| work_keys_str_mv | AT dominikasiwik pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT magdalenagajewska pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT katarzynakaron pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT kingapluta pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT mateuszwondołkowski pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT radosławwilimski pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT łukaszszarpak pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT krzysztofjfilipiak pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition AT aleksandragasecka pleiotropiceffectsofacetylsalicylicacidaftercoronaryarterybypassgraftingbeyondplateletinhibition |